Anlon Healthcare

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: INE0Y8W01025
  • NSEID: AHCL
  • BSEID: 544497
INR
14.47
-0.05 (-0.34%)
BSENSE

Aug 11

BSE+NSE Vol: 15.14 lacs

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy
Comparison
Company
Score
Quality
Valuation
Financial
Technical
Kilitch Drugs
Wanbury
Kopran
Shree Ganesh Rem
Anuh Pharma
Bafna Pharma.
Anlon Healthcare
Amanta Healthcar
Zim Laboratories
Influx Health.
Remus Pharma.
Why is Anlon Healthcare Ltd ?
Icon
Unrated Stock - No Analysis Available
stock-recommendationReal-Time Research Report
Verdict Report
How much should you sell?
  1. All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Icon
No Data Found
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors
Factor
Value
Sales Growth (5y)
65.60%
EBIT Growth (5y)
58.45%
EBIT to Interest (avg)
9.26
Debt to EBITDA (avg)
2.57
Net Debt to Equity (avg)
0.70
Sales to Capital Employed (avg)
0.86
Tax Ratio
30.12%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
2.89%
ROCE (avg)
9.07%
ROE (avg)
0
stock-recommendationValuation
Valuation Scorecard stock-summary
stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary
Factor
Value
P/E Ratio
30
Industry P/E
37
Price to Book Value
3.59
EV to EBIT
17.11
EV to EBITDA
16.54
EV to Capital Employed
3.42
EV to Sales
4.50
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
19.58%
ROE (Latest)
13.56%
Loading Valuation Snapshot...
stock-recommendationTechnicals
Technical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
RSI
No Signal
Bollinger Bands
Sideways
Moving Averages
Mildly Bullish (Daily)
KST
Bullish
Dow Theory
No Trend
Mildly Bullish
OBV
No Trend
No Trend
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
Analyse All Technical Factors stock-recommendation
stock-recommendationFinancial Trend
Financial Trend Scorecard stock-summary
stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

2What is working for the Company
NET SALES(9M)

At Rs 121.98 cr has Grown at 33.18%

-9What is not working for the Company
PAT(Q)

At Rs 4.80 cr has Fallen at -31.0% (vs previous 4Q average

NET SALES(Q)

Lowest at Rs 30.98 cr

Loading Valuation Snapshot...
Here's what is not working for Anlon Healthcare
Net Sales - Quarterly
At Rs 30.98 cr has Fallen at -29.8% (vs previous 4Q average)
over average Net Sales of the previous four quarters of Rs 44.13 Cr
MOJO Watch
Near term sales trend is very negative

Net Sales (Rs Cr)

Profit After Tax (PAT) - Quarterly
At Rs 4.80 cr has Fallen at -31.0% (vs previous 4Q average)
over average PAT of the previous four quarters of Rs 6.95 Cr
MOJO Watch
Near term PAT trend is very negative

PAT (Rs Cr)

Net Sales - Quarterly
Lowest at Rs 30.98 cr
in the last five quarters
MOJO Watch
Near term sales trend is negative

Net Sales (Rs Cr)

Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther

Name: MOJO Markets Private Limited (Research Entity) (SEBI Registration No. INH000021942) (CIN:U74900MH2015PTC264951)

Registered & Correspondence Address: Benefice Business House, Office No. 3B, 3rd Floor, C.S. 242, Mathuradas Mills Estate, N.M. Joshi Marg, Tulsi Pipe Road, Lower Parel West, Mumbai- 400013

For queries or grievances, please contact us on support.ra@mojomarkets.in, Phone : 022-35121239

"Investments in securities market are subject to market risks. Read all the related documents carefully before investing. Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors."